Risk assessment in pulmonary arterial hypertension
- PMID: 29599118
- DOI: 10.1183/13993003.00279-2018
Risk assessment in pulmonary arterial hypertension
Conflict of interest statement
Conflict of interest: A. Boucly reports personal fees and non-financial support from Actelion, and non-financial support from GlaxoSmithKline and Merck, outside the submitted work. Conflict of interest: J. Weatherald reports grants from the European Respiratory Society and the Canadian Thoracic Society, during the conduct of the study, as well as personal fees and non-financial support from Actelion Pharmaceuticals and non-financial support from Bayer, for travel to scientific meetings outside the submitted work. Conflict of interest: M. Humbert reports grants, personal fees and non-financial support from Actelion, Bayer, GlaxoSmithKline and Merck, and personal fees from Arena and Novartis, all outside the submitted work. Conflict of interest: O. Sitbon reports grants, personal fees and non-financial support from Actelion, Bayer, GlaxoSmithKline and Merck, and personal fees from Arena, all outside the submitted work.
Comment on
-
Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension.Eur Respir J. 2017 Aug 3;50(2):1700889. doi: 10.1183/13993003.00889-2017. Print 2017 Aug. Eur Respir J. 2017. PMID: 28775050
-
Risk assessment in pulmonary arterial hypertension.Eur Respir J. 2018 Mar 29;51(3):1702606. doi: 10.1183/13993003.02606-2017. Print 2018 Mar. Eur Respir J. 2018. PMID: 29599117 No abstract available.
Similar articles
-
Risk assessment in pulmonary arterial hypertension.Eur Respir J. 2018 Mar 29;51(3):1702606. doi: 10.1183/13993003.02606-2017. Print 2018 Mar. Eur Respir J. 2018. PMID: 29599117 No abstract available.
-
Risk assessment in patients with systemic sclerosis and pulmonary arterial hypertension.Eur Respir J. 2018 Oct 18;52(4):1801745. doi: 10.1183/13993003.01745-2018. Print 2018 Oct. Eur Respir J. 2018. PMID: 30337490 No abstract available.
-
Validation of a risk assessment instrument for pulmonary arterial hypertension.Eur Heart J. 2018 Dec 14;39(47):4182-4185. doi: 10.1093/eurheartj/ehx301. Eur Heart J. 2018. PMID: 28637288 No abstract available.
-
[Echocardiography and other imaging modalities in pulmonary arterial hypertension].Anadolu Kardiyol Derg. 2010 Aug;10 Suppl 1:27-35. doi: 10.5152/akd.2010.116. Anadolu Kardiyol Derg. 2010. PMID: 20819764 Review. Turkish.
-
Diagnosis of pulmonary arterial hypertension.Clin Chest Med. 2013 Dec;34(4):665-81. doi: 10.1016/j.ccm.2013.09.001. Epub 2013 Oct 17. Clin Chest Med. 2013. PMID: 24267297 Review.
Cited by
-
Risk Stratification in Pulmonary Arterial Hypertension: Do Not Forget the Patient Perspective.Am J Respir Crit Care Med. 2021 Mar 15;203(6):675-677. doi: 10.1164/rccm.202012-4350ED. Am J Respir Crit Care Med. 2021. PMID: 33357026 Free PMC article. No abstract available.
-
The 6th World Symposium on Pulmonary Hypertension: what's old is new.F1000Res. 2019 Jun 19;8:F1000 Faculty Rev-888. doi: 10.12688/f1000research.18811.1. eCollection 2019. F1000Res. 2019. PMID: 31249672 Free PMC article. Review.
-
Residual risk identified in routine noninvasive follow-up assessments in pulmonary arterial hypertension.ERJ Open Res. 2023 May 30;9(3):00072-2023. doi: 10.1183/23120541.00072-2023. eCollection 2023 May. ERJ Open Res. 2023. PMID: 37260464 Free PMC article.
-
HDL Cholesterol as a Marker of Disease Severity and Prognosis in Patients with Pulmonary Arterial Hypertension.Int J Mol Sci. 2019 Jul 18;20(14):3514. doi: 10.3390/ijms20143514. Int J Mol Sci. 2019. PMID: 31323735 Free PMC article. Review.
-
Regular Risk Assessment in Pulmonary Arterial Hypertension - A Whistleblower for Hidden Disease Progression.Acta Cardiol Sin. 2022 Mar;38(2):113-123. doi: 10.6515/ACS.202203_38(2).20211005A. Acta Cardiol Sin. 2022. PMID: 35273432 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical